These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 8120553

  • 1. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
    Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ.
    J Clin Oncol; 1994 Mar; 12(3):553-9. PubMed ID: 8120553
    [Abstract] [Full Text] [Related]

  • 2. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
    Sewak S, Sorich J, O'Leary J.
    Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
    [Abstract] [Full Text] [Related]

  • 3. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
    Blaney SM, Balis FM, Cole DE, Craig C, Reid JM, Ames MM, Krailo M, Reaman G, Hammond D, Poplack DG.
    Cancer Res; 1993 Mar 01; 53(5):1032-6. PubMed ID: 8439950
    [Abstract] [Full Text] [Related]

  • 4. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA, Hargis JB, Lilenbaum RC, Fields SZ, Rosner GL, Schilsky RL.
    J Clin Oncol; 1994 Dec 01; 12(12):2743-50. PubMed ID: 7527456
    [Abstract] [Full Text] [Related]

  • 5. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
    Creemers GJ, Gerrits CJ, Eckardt JR, Schellens JH, Burris HA, Planting AS, Rodriguez GI, Loos WJ, Hudson I, Broom C, Verweij J, Von Hoff DD.
    J Clin Oncol; 1997 Mar 01; 15(3):1087-93. PubMed ID: 9060549
    [Abstract] [Full Text] [Related]

  • 6. A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
    Kakolyris S, Kouroussis C, Souglakos J, Mavroudis D, Agelaki S, Kalbakis K, Androulakis N, Vardakis N, Vamvakas L, Georgoulias V.
    Oncology; 2001 Mar 01; 61(4):265-70. PubMed ID: 11721172
    [Abstract] [Full Text] [Related]

  • 7. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.
    Burris HA, Awada A, Kuhn JG, Eckardt JR, Cobb PW, Rinaldi DA, Fields S, Smith L, Von Hoff DD.
    Anticancer Drugs; 1994 Aug 01; 5(4):394-402. PubMed ID: 7949242
    [Abstract] [Full Text] [Related]

  • 8. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
    Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Blum RH, Zeleniuch-Jacquotte A.
    Clin Cancer Res; 1997 Aug 01; 3(8):1245-52. PubMed ID: 9815806
    [Abstract] [Full Text] [Related]

  • 9. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
    Pentheroudakis G, Briasoulis E, Karavassilis V, Mauri D, Tzamakou E, Rammou D, Pavlidis N.
    Chemotherapy; 2005 May 01; 51(2-3):154-61. PubMed ID: 15886476
    [Abstract] [Full Text] [Related]

  • 10. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
    Lilenbaum RC, Miller AA, Batist G, Bernard S, Hollis DR, Rosner GL, Egorin MJ, Schilsky RL, Ratain MJ.
    J Clin Oncol; 1998 Oct 01; 16(10):3302-9. PubMed ID: 9779705
    [Abstract] [Full Text] [Related]

  • 11. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
    Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH.
    J Clin Oncol; 1992 Apr 01; 10(4):647-56. PubMed ID: 1312588
    [Abstract] [Full Text] [Related]

  • 12. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
    Herben VM, van Gijn R, Schellens JH, Schot M, Lieverst J, Hillebrand MJ, Schoemaker NE, Porro MG, Beijnen JH, ten Bokkel Huinink WW.
    J Clin Oncol; 1999 Jun 01; 17(6):1906-14. PubMed ID: 10561232
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.
    Royce ME, Hoff PM, Dumas P, Lassere Y, Lee JJ, Coyle J, Ducharme MP, De Jager R, Pazdur R.
    J Clin Oncol; 2001 Mar 01; 19(5):1493-500. PubMed ID: 11230496
    [Abstract] [Full Text] [Related]

  • 15. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.
    Tubergen DG, Stewart CF, Pratt CB, Zamboni WC, Winick N, Santana VM, Dryer ZA, Kurtzberg J, Bell B, Grier H, Vietti TJ.
    J Pediatr Hematol Oncol; 1996 Nov 01; 18(4):352-61. PubMed ID: 8888741
    [Abstract] [Full Text] [Related]

  • 16. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
    Lilenbaum RC, Ratain MJ, Miller AA, Hargis JB, Hollis DR, Rosner GL, O'Brien SM, Brewster L, Green MR, Schilsky RL.
    J Clin Oncol; 1995 Sep 01; 13(9):2230-7. PubMed ID: 7545219
    [Abstract] [Full Text] [Related]

  • 17. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.
    Frangoul H, Ames MM, Mosher RB, Reid JM, Krailo MD, Seibel NL, Shaw DW, Steinherz PG, Whitlock JA, Holcenberg JS.
    Clin Cancer Res; 1999 Dec 01; 5(12):3956-62. PubMed ID: 10632325
    [Abstract] [Full Text] [Related]

  • 18. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum.
    Brown JV, Peters WA, Rettenmaier MA, Karlan BY, Dillman RA, Smith MR, Drescher CW, Micha JP.
    Gynecol Oncol; 2000 Dec 01; 79(3):495-8. PubMed ID: 11104627
    [Abstract] [Full Text] [Related]

  • 19. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
    van Warmerdam LJ, ten Bokkel Huinink WW, Rodenhuis S, Koier I, Davies BE, Rosing H, Maes RA, Beijnen JH.
    J Clin Oncol; 1995 Jul 01; 13(7):1768-76. PubMed ID: 7602366
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.